Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA

Endocrine therapies such as tamoxifen and aromatase inhibitors are the standard treatment options for estrogen receptor-positive breast cancer patients. However, resistance to these agents has become a major clinical obstacle. Potential mechanisms of resistance to endocrine therapies have been identified, often involving enhanced growth factor signaling and changes in the expression or action of the estrogen receptor, but few studies have addressed the role of noncoding RNA (ncRNA). Two important types of ncRNA include microRNA (miRNA) and long noncoding RNA (lncRNA). miRNAs are small RNA molecules that regulate gene expression via translational inhibition or degradation of mRNA transcripts, while lncRNAs are larger RNA molecules that have been shown to play a role in multiple cellular maintenance functions such as protein scaffolding, chromatin looping, and regulation of mRNA stability. Both miRNA and lncRNA have recently impacted the field of breast cancer research as important pieces in the mechanistic puzzle of the genes and pathways involved in breast cancer development and progression. This review serves as an overview of the roles of miRNA and lncRNA in breast cancer progression and the development of endocrine resistance. Ideally, future experiments in the field should include identification of ncRNAs that could be potential therapeutic targets in endocrine-resistant tumors, as well as ncRNA biomarkers that facilitate more tumor-specific treatment options for endocrine-resistant breast cancer patients.

[1]  S. Sleijfer,et al.  High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer , 2011, Breast Cancer Research and Treatment.

[2]  B. Katzenellenbogen,et al.  Tamoxifen down-regulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance , 2011, Oncogene.

[3]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[4]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.

[5]  Lei He,et al.  Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  V. Jordan,et al.  Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. , 1988, Cancer research.

[7]  S. Fuqua,et al.  Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. , 2009, Cancer research.

[8]  C. Klinge.  miRNAs and estrogen action , 2012, Trends in Endocrinology & Metabolism.

[9]  V. Jordan,et al.  Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer , 2009, The Journal of Steroid Biochemistry and Molecular Biology.

[10]  E. Simpson.  Sources of estrogen and their importance , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  D. Greenblatt,et al.  Interactions of tamoxifen, N‐desmethyltamoxifen and 4‐hydroxytamoxifen with P‐glycoprotein and CYP3A , 2004, Biopharmaceutics & drug disposition.

[12]  H. Burris,et al.  Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway , 2013, Cancer Chemotherapy and Pharmacology.

[13]  John W M Martens,et al.  Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer , 2008, Proceedings of the National Academy of Sciences.

[14]  C. Klinge,et al.  Reduced Expression of miR-200 Family Members Contributes to Antiestrogen Resistance in LY2 Human Breast Cancer Cells , 2013, PloS one.

[15]  A. Jaiswal,et al.  The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer , 2012, Breast Cancer Research and Treatment.

[16]  D. Cittelly,et al.  Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors , 2010, Carcinogenesis.

[17]  F. Orso,et al.  miR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2. , 2013, The American journal of pathology.

[18]  A. Brodie,et al.  Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. , 2003, Cancer research.

[19]  L. Chow,et al.  Aromatase inhibitor treatment of breast cancer cells increases the expression of let‐7f, a microRNA targeting CYP19A1 , 2012, The Journal of pathology.

[20]  R. Pazdur,et al.  FDA drug approval summaries: fulvestrant. , 2002, The oncologist.

[21]  Dustin Anderson,et al.  Delivery materials for siRNA therapeutics. Nat Mater , 2013 .

[22]  J. Foekens,et al.  Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer. , 2013, Cancer research.

[23]  T. Tuschl,et al.  Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. , 2004, Molecular cell.

[24]  A. Bader.  miR-34 – a microRNA replacement therapy is headed to the clinic , 2012, Front. Gene..

[25]  V. Giguère,et al.  Ligand-independent coactivation of ERα AF-1 by steroid receptor RNA activator (SRA) via MAPK activation , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  H. Hollema,et al.  Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma , 2009, BMC Cancer.

[27]  Jeannie T. Lee,et al.  Long Noncoding RNAs: Past, Present, and Future , 2013, Genetics.

[28]  M. Rosenfeld,et al.  LncRNA-Dependent Mechanisms of Androgen Receptor-regulated Gene Activation Programs , 2013, Nature.

[29]  William P Schiemann,et al.  TGF-β upregulates miR-181a expression to promote breast cancer metastasis. , 2013, The Journal of clinical investigation.

[30]  Olga Kovalchuk,et al.  Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin , 2008, Molecular Cancer Therapeutics.

[31]  Leonard D. Goldstein,et al.  MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype , 2007, Genome Biology.

[32]  S. Sleijfer,et al.  BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib , 2012, British Journal of Cancer.

[33]  G. Greene,et al.  Differences between estrogen- and antiestrogen-estrogen receptor complexes from human breast tumors identified with an antibody raised against the estrogen receptor. , 1984, Cancer research.

[34]  J. Lieberman,et al.  let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells , 2007, Cell.

[35]  Fergus J Couch,et al.  Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Dipali Sharma,et al.  Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. , 2005, Molecular endocrinology.

[37]  G. Chrousos,et al.  Noncoding RNA Gas5 Is a Growth Arrest– and Starvation-Associated Repressor of the Glucocorticoid Receptor , 2010, Science Signaling.

[38]  P. M. Das,et al.  Downregulation of miR-342 is associated with tamoxifen resistant breast tumors , 2010, Molecular Cancer.

[39]  Chawnshang Chang,et al.  An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol , 1992, Molecular and Cellular Endocrinology.

[40]  J. López,et al.  CD44 attenuates metastatic invasion during breast cancer progression. , 2005, Cancer research.

[41]  A. Gabory,et al.  The H19 locus acts in vivo as a tumor suppressor , 2008, Proceedings of the National Academy of Sciences.

[42]  R. Clarke,et al.  Molecular and pharmacological aspects of antiestrogen resistance , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[43]  Howard Y. Chang,et al.  Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis , 2010, Nature.

[44]  J. Lewis-Wambi,et al.  Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death , 2015, Breast Cancer Research.

[45]  Shiuan Chen.  An "omics" approach to determine the mechanisms of acquired aromatase inhibitor resistance. , 2011, Omics : a journal of integrative biology.

[46]  Miguel Beato,et al.  Steroid hormone receptors: Many Actors in search of a plot , 1995, Cell.

[47]  T. Stopka,et al.  Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum , 2014, BMC Cancer.

[48]  Wei Wu,et al.  miR-150 Promotes Human Breast Cancer Growth and Malignant Behavior by Targeting the Pro-Apoptotic Purinergic P2X7 Receptor , 2013, PloS one.

[49]  A. Brenner,et al.  Abstract CT327: Multicenter phase I study of MRX34, a first-in-class microRNA miR-34 mimic liposomal injection , 2014 .

[50]  A. Lal,et al.  MicroRNAs and their target gene networks in breast cancer , 2010, Breast Cancer Research.

[51]  J. Thomsen,et al.  Mechanisms of estrogen action. , 2001, Physiological reviews.

[52]  Yate-Ching Yuan,et al.  The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells , 2010, Breast Cancer Research and Treatment.

[53]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[54]  S. Sleijfer,et al.  MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer , 2011, Breast Cancer Research and Treatment.

[55]  Lin Zhang,et al.  The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis , 2008, Nature Cell Biology.

[56]  Y Pawitan,et al.  Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer , 2013, Oncogene.

[57]  L. O’Driscoll,et al.  Investigation of MRP‐1 protein and MDR‐1 P‐glycoprotein expression in invasive breast cancer: A prognostic study , 2004, International journal of cancer.

[58]  K. Korach,et al.  The Multifaceted Mechanisms of Estradiol and Estrogen Receptor Signaling* , 2001, The Journal of Biological Chemistry.

[59]  A. Chinnaiyan,et al.  The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. , 2014 .

[60]  Marja Moerkens,et al.  Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes , 2011, Breast Cancer Research.

[61]  B. O’Malley,et al.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.

[62]  Ming-Feng Hou,et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.

[63]  M. Rossi,et al.  LncRNAs: New Players in Apoptosis Control , 2014, International journal of cell biology.

[64]  H. Brauch,et al.  Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment. , 2013, European journal of cancer.

[65]  H. Lodish,et al.  Regulation of mammalian cell differentiation by long non‐coding RNAs , 2012, EMBO reports.

[66]  Domenico Coppola,et al.  MicroRNA-221/222 Negatively Regulates Estrogen Receptorα and Is Associated with Tamoxifen Resistance in Breast Cancer* , 2008, Journal of Biological Chemistry.

[67]  R. Brueggemeier.  Aromatase, Aromatase Inhibitors, and Breast Cancer , 2001, American journal of therapeutics.

[68]  T. Dupressoir,et al.  Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. , 2002, Carcinogenesis.

[69]  W. Filipowicz,et al.  The widespread regulation of microRNA biogenesis, function and decay , 2010, Nature Reviews Genetics.

[70]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[71]  R. Blamey,et al.  Estrogen receptors and breast cancer. , 1981, Environmental health perspectives.

[72]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[73]  Katie B Bennett,et al.  The Role of MicroRNAs in Breast Cancer. , 2011, Journal of the Association of Genetic Technologists.

[74]  David A. Flockhart,et al.  Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[75]  T. Taguchi,et al.  Immunohistochemical detection of P-glycoprotein in breast cancer and its significance as a prognostic factor , 1997, Breast cancer.

[76]  R. García-Becerra,et al.  Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance , 2012, International journal of molecular sciences.

[77]  M. Mourtada-Maarabouni,et al.  GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer , 2009, Oncogene.

[78]  L. Dorssers,et al.  Functional Screen for Genes Responsible for Tamoxifen Resistance in Human Breast Cancer Cells , 2006, Molecular Cancer Research.

[79]  D. Amadori,et al.  miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis , 2013, Nature Cell Biology.

[80]  A. Brodie,et al.  Aromatase Inhibitors and Breast Cancer , 2009, Annals of the New York Academy of Sciences.

[81]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[82]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.

[83]  P. Lønning,et al.  In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[84]  R. Weksberg,et al.  Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1. , 2001, Human molecular genetics.

[85]  Tianyu Li,et al.  Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. , 2005, Journal of the National Cancer Institute.

[86]  Danielle Meijer,et al.  Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells , 2011, Journal of cellular physiology.

[87]  Myles Brown,et al.  Loss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer. , 2015, Cancer research.

[88]  Xing Chen,et al.  LncRNADisease: a database for long-non-coding RNA-associated diseases , 2012, Nucleic Acids Res..

[89]  Hong Wang,et al.  Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice. , 2006, Cancer research.

[90]  J. Foekens,et al.  Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer , 2010, British Journal of Cancer.

[91]  K. Venkatesh,et al.  Non-coding RNA interact to regulate neuronal development and function , 2014, Front. Cell. Neurosci..

[92]  P. Chambon,et al.  Functional domains of the human estrogen receptor , 1987, Cell.

[93]  P. Lønning,et al.  Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  K. Morris,et al.  The rise of regulatory RNA , 2014, Nature Reviews Genetics.

[95]  Javed Siddiqui,et al.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.

[96]  J. Pink,et al.  An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. , 1995, Cancer research.

[97]  S. Lottin,et al.  Steroid hormones modulate H19 gene expression in both mammary gland and uterus , 1999, Oncogene.

[98]  A. Bhan,et al.  Antisense transcript long noncoding RNA (lncRNA) HOTAIR is transcriptionally induced by estradiol. , 2013, Journal of molecular biology.

[99]  E. Levin,et al.  Integration of the extranuclear and nuclear actions of estrogen. , 2005, Molecular endocrinology.

[100]  H. Binder,et al.  Novel circulating microRNA signature as a potential non‐invasive multi‐marker test in ER‐positive early‐stage breast cancer: A case control study , 2014, Molecular oncology.

[101]  A. Ashworth,et al.  FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. , 2010, Cancer research.

[102]  Gauri Sabnis,et al.  Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. , 2005, Cancer research.

[103]  M. Kitagawa,et al.  Cell cycle regulation by long non-coding RNAs , 2013, Cellular and Molecular Life Sciences.

[104]  Daniel Anderson,et al.  Delivery materials for siRNA therapeutics. , 2013, Nature materials.

[105]  Hailong Wu,et al.  MicroRNA-101-mediated Akt activation and estrogen-independent growth , 2011, Oncogene.

[106]  R. Kim,et al.  Endoxifen, the Active Metabolite of Tamoxifen, Is a Substrate of the Efflux Transporter P-Glycoprotein (Multidrug Resistance 1) , 2011, Drug Metabolism and Disposition.

[107]  Y. Ito,et al.  Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. , 1994, Endocrine reviews.

[108]  Howard Y. Chang,et al.  Long Noncoding RNA as Modular Scaffold of Histone Modification Complexes , 2010, Science.

[109]  V. Beneš,et al.  Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. , 2009, Cancer research.

[110]  Ö. Sahin,et al.  MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer , 2014, The Journal of pathology.

[111]  Eric A. Ariazi,et al.  Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time , 2011, Proceedings of the National Academy of Sciences.

[112]  Weiying Zhou,et al.  UC Office of the President Recent Work Title De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer , 2012 .